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Abstract 
Risperidone is a second-generation antipsychotic medications that can significantly improve cognitive function 
in schizophrenic patients. The objective of the present study is to determine the effectiveness of risperidone on 
cognitive function for improving the Mini Mental State Examination( MMSE) and  Clock Drawing Test (CDT) 
scores. A total of 30 samples of schizophrenic patients who received risperidone treatment (27 men and 3 
women), attending the outpatient in mental health hospital in Sumatera Utara, autoanamnese undergo direct 
interview using a measurement scale BPRS then undergo examination MMSE and CDT scores, the study was 
conducted for 8 weeks (pre and post test). From this study found that the risperidone effectively improves 
cognitive function in schizophrenic patients based on the presence of significant differences in MMSE and CDT 
scores (p = 0.0001). 
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1. Introduction 
Using second-generation antipsychotic medications can significantly improve cognitive functioning in 
schizophrenic patients (Herrmann et al, 1999; Arana et al in handbook of psychiatry, 2000; Barkic et al, 2003; 
Muller et al, 2005; Golberg et al, 2007; Marder et al in Kaplan & Sadock’s, 2009; Dania, 2009). Schizophrenic 
patients showed a high correlation with MMSE average of 0.40 until 0.54. The validity of the measurements 
should be tested by determining cooperation with other neuropsychological tests that are widely used to assess 
cognitive function in schizophrenic patients.  CDT is sensitive enough to detect cognitive impairment attached to 
in schizophrenia, also in addition to correlate with the severity of symptoms (Bozikas et al, 2002; Bozikas et al, 
2004). 
 
2. Subject and Methods 
This study was approved by the Research Ethics Committee of Medical Faculty University of Sumatera Utara. 
This study was performed in Mental Hospital of Province of North Sumatera, on the regulation of Medical 
Faculty of University of North Sumatera, from of March 1, 2010 until August 31, 2010. The criteria inclusion for 
subject were age 20 – 50 years old, meet the criteria PPDGJ-III, willing as research subjects, first contact with 
the researcher, and co-operative acute phase . We excluded of patients with schizophrenia are common and 
comorbid medical illness or other psychiatric disorders, state of pregnancy and lactation, hypersensitivity to 
risperidone, not graduated from high school / equivalent. Written informed consent was obtained from all 
participants after giving a full explanation of the study protocol.  Autoanamnese undergo direct interview using a 
measurement scale BPRS then underwent MMSE and CDT. The results of the measurement scale BPRS, MMSE 
and CDT scores at baseline before treatment than after the eighth week of treatment. 
 
2.1 Assessment and Rating 
First, the patient will be measured using the BPRS severity, then the patient will undergo the MMSE and CDT in 
the acute phase before getting treatment interventions. Thirty samples will be interfered with risperidone. Every 
two weeks the patient was observed and the dose titrated. The initial dose of risperidone 2 mg / day every 2 
weeks was observed and the dose titrated slowly until it reached 4 mg/day for 8 weeks. If the patient does not 
achieve clinical remission after 2 weeks of administration of risperidone, the patient was considered 
unresponsive to treatment with risperidone and excluded in this study. Furthermore, the patients will be given 
treatment with other antipsychotics. During the study, additional drugs may be administered to the patient is 
limited to trihexypenidyl a dose of 4 mg/day(split into two feedings). Then re-examination in the eight week, to 
assess the severity of schizophrenic patients used a scale of measurement to assess the BPRS and improvement 
of cognitive function used MMSE and CDT scores.  Assessment results MMSE and CDT scores at baseline 
before treatment with after the eighth week of treatment assessed whether there was an improvement.  MMSE 
scores had been translated in Indonesian of 21-26 as mild, moderate 10-20, further <10 (Wibisono, 2003) and 
CDT scores consisting of drawing circle hours maximum value 1, writing correct clock rate maximum value 1, 
putting numbers correct hour maximum value 1, shows clockwise corret maximum value 1. Total score of 4.  
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CDT which has been modified (Martina, 2010). 
 
2.2 Statistical Analysis 
Analytical studies with experimental approaches One group pre test - post test design to see the effect of 
improving the effectiveness of risperidone on scores Mini Mental State Examination and the Clock Drawing Test 
in schizophrenic patients. The results of MMSE and CDT scores at the time before and after treatment 
incorporated into the data and then tabulated and processed. Statistical analysis using the chi-square. Processing 
and data analysis using SPSS statistical test. From the independent t-test values seen no significant difference 
between the mean value comparison 2 groups of BPRS, MMSE and CDT before and after (p = 0.001). 
 
3. Result 
Table 1. Distribution of the study sample based on demographic characteristics. 
Varibel n % 
Age 
21 – 30 
31 – 40 
41 – 50 
 
12 
13 
5 
 
40,0 
43,3 
16,7 
Gender 
Male 
Female 
 
27 
3 
 
90,0 
10,0 
Level of education  
    High School / equivalent  
    Higher Education 
 
26 
4 
 
86,7 
13,3 
 
From table 1. sample is at most 31-40 year age group were 13 persons (43.3%), male gender as many as 27 
people (90%), education level of high school / equivalent were 26 people (86.7%). 
 
Table 2. Statistical sample pairs 
 n Mean Standard deviation  
BPRS  1 
BPRS  8 
30 
30 
39,00 
16,93 
2,5 
2,3 
 MMSE 1 
  MMSE  8 
30 
30 
15,40 
24,53 
3,2 
3,0 
                CDT  1 
                CDT  8 
30 
30 
1,37 
3,47 
0,5 
0,6 
 
From table 2. Observed that of the T-test idenpendent: Average value of the first week of BPRS  
 = 39.0 (SD 2.5), MMSE = 15.40 (SD 3.2), and CDT = 1.37 (SD 0.5). Average value of the eighth week of 
BPRS = 16.93 (SD 2.3), MMSE = 24.53 (SD 3.0), CDT = 3.47 (SD 0.6). 
 
Table 3. Samples test of different pairs 
 Mean Standard deviation P* 
BPRS1-BPRS8 22,07 3,00 0,00 
MMSE1-MMSE8 -9,13 4,56 0,00 
CDT1-CDT8 -2,10 0,71 0,00 
P* independent samples test 
 
From table 3. Independent t-test shown no significant difference between the mean value comparison 2 groups of 
BPRS, MMSE and CDT before and after p = 0.001 
 
4. Discussion 
This study shows that the effectiveness of risperidone may improve cure rates of schizophrenic patients using a 
measurement scale BPRS and may improve cognitive function using the MMSE and CDT screening tool. The 
results of this study can’t directly express the effectiveness of risperidone may improve cognitive function or as a 
whole can be assessed that the schizophrenic patients, the better the better the prognosis will also cognitive 
function. 
The results of this study are not in accordance with the results of study that shows the CDT test is more 
sensitive to cognitive impairment than the MMSE (Herrmann et al, 1999). The results of this experiment are also 
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not consistent with studies showing schizophrenic patients showed a high correlation with the MMSE, but there 
is a change in the administration of medication cognitive function (Bozikas et al, 2002 and Bozikas et al, 2004). 
 
5. Conclusion 
From the this study it was found that risperidone effectively improves cognitive function in schizophrenic 
patients based on the presence of significant differences in MMSE and CDT scores (p = 0.0001). 
 Treatment of schizophrenic patients should pay attention to cognitive dysfunction. Provision of atypical 
antipsychotics may be considered to improve cognitive function in schizophrenic patients. 
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